Poly (ADP-ribose) polymerase inhibitors (PARPi) have transformed the treatment landscape for homologous recombination-deficient (HRD) cancers, particularly those harboring BRCA1/2 mutations, including breast, ovarian, prostate, and pancreatic cancers, by exploiting the synthetic lethality induced by HR deficiency (HRD)...
Kousalya Lavudi, M. Renjith, Charan Pithana Sai Venkata Vijay et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.